Panel A contains four line graphs showing tumor size over time in different groups of mice. The x-axis represents time in days, and the y-axis represents tumor size in square millimeters. The graphs compare tumor growth in WT and BATF3 KO mice with different MC38 cell variants. The lower graph shows the mean tumor size with standard error of the mean (SEM) and statistical comparisons. Panel B includes a scatter plot and histograms. The scatter plot shows the percentage of TNFR1 positive cells in tumors, with each dot representing an individual tumor. The histograms display the distribution of TNFR1 immunostaining in cell suspensions from tumors. Panel C and D contain line graphs showing tumor size over time in control mice and rechallenged polyclonal TNFR1KO mice. The x-axis represents days, and the y-axis represents tumor size in square millimeters. The upper graphs show the mean tumor size with SEM, while the lower graphs show individual tumor follow-ups.
TNFR1KO variants regain tumorigenicity in cDC1-deficient BATF3 −/− mice, in vivo assessment of TNFR1 WT:KO mixtures in Fig. 2, D and E, and tumor rechallenge experiments. (A) Comparative tumor engraftment of the indicated MC38 cell variants in WT and BATF3−/− mice is shown by individual follow-ups and mean ± SEM with two-way ANOVA statistical comparisons (lower graph) (n = 6). (B) FACS assessment of TNFR1 immunostaining of cell suspensions from tumors in Fig. 2 D, including the indicated mixtures. Each dot represents data from an individual tumor (n = 6). On the right, individual histograms are shown. (C and D) Rechallenge of the mice rejecting TNFR1KO tumors in experiments as in Fig. 1, A and B, that were rechallenged >90 days later with MC38 WT (C) or EO771 WT (D) and antigenically unrelated B16OVA in the contralateral flank (n = 6–12). Upper graphs in C and D represent mean ± SEM, and individual tumor follow-up is provided in the lower graphs. P < 0.0001 (****).